Angiomatoid Fibrous Histiocytoma: a Single Institution Case-series
1 other identifier
observational
9
1 country
1
Brief Summary
single institution cases series review of histological and clinical data
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Nov 2018
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 22, 2018
CompletedFirst Posted
Study publicly available on registry
November 30, 2018
CompletedStudy Start
First participant enrolled
November 30, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
May 25, 2019
CompletedFebruary 13, 2020
November 1, 2018
5 months
November 22, 2018
February 11, 2020
Conditions
Outcome Measures
Primary Outcomes (2)
selection and review of 9 cases of Angiomatoid Fibrous Histiocytoma
investigators will review all the medical records, radiological imaging, and histological slides of all cases to identify the best therapeutic approach.
at baseline (Day0)
analysis of EWS-CREB1 and EWS-ATF1 mutation and ALK expression on tissue tumor material
In all cases immunohistochemistry will be performed on slides/formalin-fixed paraffin-embedded tissue tumor material. EWS-CREB1 and EWS-ATF1 mutation and ALK expression will be analyzed with RT-PCR and/or FISH analysis.
at baseline (Day0)
Eligibility Criteria
Male and Female with diagnosis of Angiomatoid Fibrous Histiocytoma with histological slides/formalin-fixed paraffin-embedded tissue tumor blocks from archive available to perform the histology analysis
You may qualify if:
- Male and female patients treated at Rizzoli Institute from 01 January 2006 to 31 December 2017
- Diagnosis of Angiomatoid Fibrous Histiocytoma
- Histological slides/formalin-fixed paraffin-embedded tissue tumor (FFPE) blocks from archive available to perform the histology analysis
- Written informed consent prior to any study-specific analysis and/or data collection
You may not qualify if:
- Patients with histological diagnosis different from Angiomatoid Fibrous Histiocytoma
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
IRCC Rizzoli Orthopedic Institute
Bologna, 40136, Italy
Related Publications (5)
Antonescu CR, Dal Cin P, Nafa K, Teot LA, Surti U, Fletcher CD, Ladanyi M. EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer. 2007 Dec;46(12):1051-60. doi: 10.1002/gcc.20491.
PMID: 17724745RESULTBohman SL, Goldblum JR, Rubin BP, Tanas MR, Billings SD. Angiomatoid fibrous histiocytoma: an expansion of the clinical and histological spectrum. Pathology. 2014 Apr;46(3):199-204. doi: 10.1097/PAT.0000000000000073.
PMID: 24614712RESULTChen G, Folpe AL, Colby TV, Sittampalam K, Patey M, Chen MG, Chan JK. Angiomatoid fibrous histiocytoma: unusual sites and unusual morphology. Mod Pathol. 2011 Dec;24(12):1560-70. doi: 10.1038/modpathol.2011.126. Epub 2011 Aug 5.
PMID: 21822206RESULTNoujaim J, Jones RL, Swansbury J, Gonzalez D, Benson C, Judson I, Fisher C, Thway K. The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities. Br J Cancer. 2017 Feb 28;116(5):669-678. doi: 10.1038/bjc.2017.4. Epub 2017 Jan 31.
PMID: 28141799RESULTRossi S, Szuhai K, Ijszenga M, Tanke HJ, Zanatta L, Sciot R, Fletcher CD, Dei Tos AP, Hogendoorn PC. EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma. Clin Cancer Res. 2007 Dec 15;13(24):7322-8. doi: 10.1158/1078-0432.CCR-07-1744.
PMID: 18094413RESULT
Biospecimen
immunohistochemistry will be performed on FFPE material. EWS-CREB1 and EWS-ATF1 mutation and ALK expression will be analyzed with RT-PCR and/or FISH analysis.
MeSH Terms
Conditions
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 22, 2018
First Posted
November 30, 2018
Study Start
November 30, 2018
Primary Completion
May 1, 2019
Study Completion
May 25, 2019
Last Updated
February 13, 2020
Record last verified: 2018-11
Data Sharing
- IPD Sharing
- Will not share
No Individual Patient Data sharing plan has been implemented